Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Assets for 8 consecutive years, with $41.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 2.18% to $41.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $164.2 million, a 46.81% increase, with the full-year FY2024 number at $41.4 million, up 76.75% from a year prior.
  • Non-Current Assets was $41.8 million for Q3 2025 at Precision Biosciences, up from $38.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $49.7 million in Q4 2021 to a low of $18.5 million in Q3 2023.
  • A 5-year average of $38.2 million and a median of $41.8 million in 2025 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 60.12% in 2023, then surged 131.1% in 2024.
  • Precision Biosciences' Non-Current Assets stood at $49.7 million in 2021, then decreased by 21.47% to $39.1 million in 2022, then tumbled by 40.04% to $23.4 million in 2023, then soared by 76.75% to $41.4 million in 2024, then grew by 0.98% to $41.8 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Non-Current Assets are $41.8 million (Q3 2025), $38.7 million (Q2 2025), and $42.3 million (Q1 2025).